Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Dapagliflozin/metformin (Primary) ; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 01 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 01 Apr 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.